Biodexa Pharmaceuticals PLC (BDRX) Stock Analysis

$0.485

+0.186 (+38.46%)At close

Loading chart…

High: 0.540
Open: 0.498
VWAP: 0.48
Volume: 53.25M
Mkt Cap: 7.90M
Low: 0.404
Amount: 25.36M
EV/EBITDA, TTM: 0.00

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

www.biodexapharma.com

AI analysis of Biodexa Pharmaceuticals PLC (BDRX)

Sell

Biodexa Pharmaceuticals PLC (BDRX) is not a good buy right now due to its extremely low RSI of 13.171, indicating oversold conditions, and a staggering year-to-date change of -96.26%.

Valuation Metrics

The current forward P/E ratio for Biodexa Pharmaceuticals PLC (BDRX) is 0.00, compared to its 5-year average forward P/E of -61.04.

Forward P/E

Fair

5Y Average P/E

-61.04

Current P/E

0.00

Overvalued

133.72

Undervalued

-255.80

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.25

Current EV/EBITDA

0.00

Overvalued

0.84

Undervalued

-1.33

Forward P/S

Fair

5Y Average P/S

50.23

Current P/S

0.00

Overvalued

146.32

Undervalued

-45.87

Events Timeline

2026-09-24 (ET)